Head-to-head · WeighScore
BeyondMD vs Mint Med
The verdict
Mint Med takes it — 84.7/100 to 66.5/100.
Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | BeyondMD | Mint Med |
|---|---|---|
| WeighScore | 66.5/100 | 84.7/100 |
| Grade | C | B |
| Scorecard rank | #189 | #22 |
| Semaglutide | $139/mo (starting dose, compounded) | $117/mo |
| Tirzepatide | $209/mo (starting dose, compounded) | $159/mo |
| Coverage | Coverage not published | 36 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #189 · C
Strengths
- Aggressively low monthly pricing
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Graded #22 · B
Strengths
- $117 sema / $159 tirz
- LegitScript-verified
- Both molecules
Where it loses points
- Only 36 states
- Injection-only
- Monitoring detail sparse
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.